STELLA has reached 813 enrolled participants across 14 centers in 6 Latin American countries, less than 18 months after the launch of the prospective cohort in November 2024. Enrollment now spans Argentina, Brazil, Chile, Colombia, Mexico, and Peru.
November 2024 — Prospective cohort launch.
Following the retrospective phase that established the scientific case for a dedicated Latin American cohort, the STELLA prospective study officially opened enrollment in November 2024 with a coordinated activation across partner sites.
Publications
Latin America carries one of the highest burdens of steatotic liver disease in the world.
2025 — Inherited genetic risk of liver fibrosis in lean versus nonlean MASLD published in Alimentary Pharmacology & Therapeutics. [Read more →](#publications)
2025 — Disparities in screening and risk stratification for Hispanic adults with MASLD published in Hepatology. [Read more →](#publications)
2025 — Third STELLA paper published in Journal of Hepatology. [Full citation pending.]
Conference presentations
2025 ALEH Congress — First cross-sectional baseline analysis of 370 STELLA MASLD participants across 10 centers presented; abstract published in Annals of Hepatology.
[Add upcoming AASLD, EASL, ALEH, and DDW presentations as they are accepted.]
New centers
[Announce each new center with a short paragraph: name, location, site PI, and date of activation.]
Newsletter signup
Interested in receiving STELLA updates 2–3 times per year? Enter your email below.